Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01377532 | Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma | approved for marketing | — | — | University of California, San FranciscoOTHER | 1 | May 6, 2020 | clinicaltrials |
| NCT04136808 | An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma | approved for marketing | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 1 |
| Jan 13, 2020 |
| clinicaltrials |
| NCT01632826 | Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma(PEXIUS) | approved for marketing | — | — | CelgeneINDUSTRY | 2 | Nov 12, 2019 | clinicaltrials |
| NCT03089658 | Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC) | approved for marketing | — | — | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 9, 2019 | clinicaltrials |
| NCT02436044 | HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC | approved for marketing | — | — | Ming ZhaoOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT00684385 | An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck | approved for marketing | — | — | AstraZenecaINDUSTRY | 4 | Mar 14, 2019 | clinicaltrials |
| NCT02961491 | Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | approved for marketing | — | — | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02477891 | Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 6 | Jan 15, 2019 | clinicaltrials |
| NCT03533361 | Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil | approved for marketing | — | — | Eisai Inc.INDUSTRY | 1 | Dec 17, 2018 | clinicaltrials |
| NCT01931306 | Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC) | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00683306 | Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment | approved for marketing | — | — | AstraZenecaINDUSTRY | 19 | Sep 13, 2018 | clinicaltrials |
| NCT03245424 | Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation | approved for marketing | — | — | Agios Pharmaceuticals, Inc.INDUSTRY | 0 | Jul 24, 2018 | clinicaltrials |
| NCT02705313 | EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx | approved for marketing | — | — | Advanced Accelerator ApplicationsINDUSTRY | 1 | Apr 9, 2018 | clinicaltrials |
| NCT01869803 | Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia | approved for marketing | — | — | Wake Forest University Health SciencesOTHER | 1 | Mar 2, 2018 | clinicaltrials |
| NCT01592136 | Expanded Access Program of Ponatinib | approved for marketing | — | — | Ariad PharmaceuticalsINDUSTRY | 1 | Feb 6, 2018 | clinicaltrials |
| NCT02792725 | Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 1 | Oct 31, 2017 | clinicaltrials |
| NCT03079687 | Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | approved for marketing | — | — | AstraZenecaINDUSTRY | 1 | Oct 25, 2017 | clinicaltrials |
| NCT01410500 | Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease | approved for marketing | — | — | AmgenINDUSTRY | 0 | May 2, 2017 | clinicaltrials |
| NCT03025867 | Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer | approved for marketing | — | — | Tesaro, Inc.INDUSTRY | 0 | Apr 17, 2017 | clinicaltrials |
| NCT01217697 | Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer | approved for marketing | — | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 24 | Mar 24, 2017 | clinicaltrials |
| NCT02437019 | Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | approved for marketing | — | — | Janssen-Cilag Farmaceutica Ltda.INDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT01606982 | Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | approved for marketing | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Feb 17, 2017 | clinicaltrials |
| NCT02355054 | Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study | approved for marketing | — | — | Washington University School of MedicineOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT01649284 | Afatinib Expanded Access Program | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 30, 2016 | clinicaltrials |
| NCT01209650 | LUX Lung Special Access Scheme Australia Named Patient Use (NPU) | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 10, 2016 | clinicaltrials |
| NCT02589717 | An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00338247 | EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer | approved for marketing | — | — | NovartisINDUSTRY | 45 | Apr 6, 2016 | clinicaltrials |
| NCT02211222 | An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer | approved for marketing | — | — | Eisai Inc.INDUSTRY | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01160250 | A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Aug 6, 2015 | clinicaltrials |
| NCT01240421 | An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory | approved for marketing | — | — | Eisai Inc.INDUSTRY | 3 | May 22, 2015 | clinicaltrials |
| NCT02136511 | Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia | approved for marketing | — | — | Gilead SciencesINDUSTRY | 4 | Oct 28, 2014 | clinicaltrials |
| NCT00481559 | Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity | approved for marketing | — | — | BTG International Inc.OTHER | 0 | Jan 17, 2014 | clinicaltrials |
| NCT01683110 | Expanded Access of Cabozantinib in Medullary Thyroid Cancer | approved for marketing | — | — | ExelixisINDUSTRY | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00905593 | Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(ENACT) | approved for marketing | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 18, 2012 | clinicaltrials |
| NCT00094029 | A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 | approved for marketing | — | — | PfizerINDUSTRY | 34 | Mar 9, 2012 | clinicaltrials |
| NCT00130897 | Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma | approved for marketing | — | — | PfizerINDUSTRY | 50 | Mar 9, 2012 | clinicaltrials |
| NCT00730444 | Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma | approved for marketing | — | — | GE HealthcareINDUSTRY | 1 | Nov 9, 2009 | clinicaltrials |
| NCT00786058 | A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003 | approved for marketing | — | — | CONKO-StudiengruppeOTHER | 0 | Jun 15, 2009 | clinicaltrials |
| NCT00040625 | ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 4 | Mar 15, 2007 | clinicaltrials |
Data updated 22 days agoSource updated May 6, 2020source: clinicaltrials